England's HPV programme now shows up in the hardest number: cervical cancer deaths

That HPV vaccination prevents cervical cancer is, by now, established: earlier work showed the disease becoming markedly rarer in vaccinated women [s2]. What has been missing is evidence on the outcome that matters most — deaths. A 2026 analysis of England's national mortality data supplies it, and the finding is striking: in the youngest, most completely vaccinated women, cervical cancer deaths have all but disappeared [s1].

What the study did

England introduced a national HPV vaccination programme in 2008 for girls aged 12–13, reaching 80–90% coverage before the COVID-19 pandemic, alongside a catch-up campaign in 2008–10 for girls aged 14–18 [s1]. Researchers analysed population-based cervical cancer mortality in England from 2001 to 2024 among women in three age bands — 20–24, 25–29 and 30–34 [s1]. Using official coverage figures by birth cohort, they estimated the proportion vaccinated for each age group and year of death, then applied Poisson regression to compare observed deaths with what would have been expected without vaccination, assuming no herd immunity [s1].

This is an observational analysis of routine data, not a trial — a point the authors are careful to make. But deaths are a hard outcome, and national mortality records are about as complete as data get.

What it found

Among women aged 20–24 between 2020 and 2024 — a group whose coverage at age 12–13 was around 88–90% — no cervical cancer deaths occurred, against 23.1 expected based on historical rates [s1]. That corresponds to a mortality reduction of 100% (95% CI, 84 to 100) [s1].

In earlier cohorts, who were offered the vaccine later, up to age 18, and reached lower coverage of around 63–87%, the reductions were large but smaller: 80% (95% CI, 51 to 94) in women aged 20–24 during 2015–19, and 69% (95% CI, 55 to 79) in women aged 25–29 during 2020–24 [s1]. Estimated at the level of vaccinated women, the relative risk reduction was 100% (95% CI, 81 to 100) in those aged 20–24, 100% (95% CI, 89 to 100) in those aged 25–29, and 63% (95% CI, −13 to 100) in those aged 30–34 — the last, oldest group vaccinated latest and least completely, with an interval wide enough to include no benefit [s1]. Up to the end of 2024, the authors estimate HPV vaccination was associated with a reduction of around 199.6 cervical cancer deaths (95% CI, 125.0 to 274.2) [s1].

Why the pattern is persuasive

The gradient is what makes this more than a correlation. The protection tracks coverage and the age at vaccination: strongest in the women vaccinated youngest and most completely, weaker in those vaccinated older and at lower uptake [s1]. That dose-response-by-cohort pattern is exactly what a causal effect should look like, and it mirrors the incidence findings reported earlier for the same programme [s2]. Vaccinating before likely exposure to the virus is the recurring lesson — the same reason catch-up cohorts, already partly exposed, saw less benefit.

How much to trust it

The headline "100% reduction" needs reading carefully. It reflects zero observed deaths in a young age band where cervical cancer deaths were always rare, so the estimate rests on a small expected number (23.1) and carries a wide confidence interval down to 84% [s1]. This is also an ecological, model-based analysis: it infers individual protection from population coverage, and it assumes no herd immunity, which if present would mean some of the credited benefit belongs to unvaccinated women shielded by vaccinated ones [s1]. The authors themselves frame the result as the first robust national-level evidence on mortality — robust, but observational [s1].

A funding note: the work was supported by Cancer Research UK, a charity, rather than a vaccine manufacturer [s1].

What it means for a reader

For parents weighing HPV vaccination for a child, this is about as direct as public-health evidence gets: the programme is now linked not just to fewer cancers but to fewer deaths, with the largest effect in those vaccinated youngest [s1]. For adults, it underscores that screening still matters, especially for older cohorts who were vaccinated late or not at all. Health Newspapers has also covered the shift to HPV-based primary cervical screening and the move toward self-collected samples. This article is informational and is not medical advice.

What to watch

Whether the mortality benefit widens as the fully vaccinated cohorts age into the years when cervical cancer deaths normally peak, and whether countries with lower or more unequal coverage can reproduce it. The 30–34 band, with its confidence interval still spanning no benefit, is where the next few years of data will be most telling [s1].

Sources

• Cervical cancer mortality trends following HPV vaccination in England, 2001-24 — The Lancet, 2026-06-17
• The effects of the national HPV vaccination programme in England, UK, on cervical cancer and CIN3 incidence — The Lancet, 2021-11-03